
TB-500 is a synthetic peptide fragment derived from thymosin beta-4 (Tβ4), an actin-sequestering protein widely distributed across human tissues. Its sequence, Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Lys-Thr-Glu-Thr-Lys-Asn-Pro-Lys-Asp-Lys-Arg-Ala-Asp-Glu-Ile-Asn-Glu-Lys, binds to G-actin and modulates cell motility and structural organization. Research has demonstrated its ability to promote new blood vessel formation, reduce inflammatory signaling, and enhance cell migration essential for tissue repair across multiple tissue types. Phase 1 human safety studies have established tolerability, and preclinical models consistently show regenerative activity in musculoskeletal, cardiac, corneal, and wound healing applications.